13:58 IST
BSE
Earnings Call
Morepen Laboratories Investor Presentation: Key Takeaways
Morepen delivers explosive Q1'FY27 growth with 207% EBITDA jump, driven by the first commercial CDMO dispatches and operational leverage. The 'Morepen 2.0' strategy shifts focus from commodity APIs to high-margin innovation-led manufacturing.